Background: An unethical clinical study that entailed withholding treatment from women diagnosed with cervical intraepithelial neoplasia 3 (CIN3) was conducted at National Women's Hospital, Auckland, New Zealand. Women with microinvasive carcinoma of the cervix also had treatment withheld.
INTRODUCTION
The past management of cervical intraepithelial neoplasia 3 (CIN3) in some women at National Women's Hospital in Auckland, New Zealand, has been controversial. In 1970, Dr G. H. Green announced:
'The only way to settle finally the problem of what happens to in situ cancer is to follow indefinitely patients with diagnosed but untreated lesions. This is being attempted…' 1 Green's study had been approved by the Hospital Medical Committee in 1966, although had actually started earlier. 2 Although regular follow-up occurred, with clinical, cytological and sometimes colposcopic examinations, persistent abnormalities were not treated in a group of women.
Serious concerns about the ethics of withholding treatment from women, as well as not seeking their consent, led to a judicial inquiry in 1987-88. Judge Silvia Cartwright concluded that the study was unethical, as well as scientifically flawed. 2 During this inquiry, the clinical records of all women were assessed and an independent clinical review was recommended when there was any doubt about the adequacy of treatment. The judge recommended that histological and other material resulting from the study should be available for future properly planned and approved research.
Previous reports have analysed the risk of invasive cancer in women with CIN3, 3, 4 and the consequences for women with CIN3 included in Green's study. 5 Despite continuing controversy about Green's research, [6] [7] [8] it is not widely known that his trial of withholding treatment also included women with microinvasive (stage 1A) cervical cancer. In fact such women were combined with those with carcinoma in situ in his publications. 9 The outcome for the women with microinvasive cancer has not previously been reported.
The pathological diagnosis of microinvasive cancer depends on removal of the complete lesion, so Green's study cannot be used to estimate the natural history of this condition. Nevertheless, many of the women who did not receive treatment with curative intent were left with persistent CIN3 at the margin of their biopsy.
There is also the possibility that separate foci of microinvasion were not detected in some cases. It is important to document the outcome for the women with microinvasive cancer who were managed in a variety of ways. Following a review of medical records, cytology and histopathology, we conducted a study of the outcomes for women with microinvasive cervical cancer.
MATERIALS AND METHODS
The methods for the study were similar to those used to estimate the natural history of CIN3, which have been described elsewhere. This is further divided into stage 1A1, where stromal invasion is ≤3 mm, and stage 1A2 where stromal invasion is >3 mm and ≤5 mm. The process for the histopathological review has been described in detail elsewhere.
4,5
We extracted information from the medical records of National There was good agreement between the original and review coding (κ = 0.79). 12 For smears in the first 24 months we used the review cytology whenever it was available. Cytology within six months after a procedure was not considered to be informative because false positives can occur due to reparative changes. were clear of CIN3, and whether or not there was cytological evidence of persisting disease in the 6-24 months after excision. In describing the initial and follow-up management, we counted numbers of positive smears and numbers of positive smears or biopsies not followed by appropriate treatment, restricted to the first 10 years after diagnosis for comparability over time.
Proportions with positive smears, untreated positive smears and additional biopsies were compared using χ 2 tests of association. For time-to-event analyses the entry date was the date of the histological diagnosis of stage 1A carcinoma of the cervix.
Competing risk methods were used to describe the cumulative incidence of stage 1B or higher cancer of the cervix or vaginal vault (death from causes other than cancer of the cervix or vagina was considered as a competing risk). 16 Analyses were carried out in Stata. 17 The study received approval from the Northern X Ethics Committee, Auckland.
RESULTS
Of the 1229 women originally diagnosed with cervical CIS or microinvasion, 95 were excluded for reasons explained elsewhere, 
respectively) ( Table 2 ). Among women who did not have curative treatment initially, the proportion who eventually had curative treatment was smaller in the group with only a small excision initially than in the group with a large excision (30% vs 48% by 15 years). However, this difference was not statistically significant (P = 0.12). Death from any cause 7 21 9 †Procedures classified as 'probably curative' were: (i) hysterectomy with clear or unknown margins and normal, benign, class 2 or no informative cytology within 6-24 months; or (ii) cone biopsy with clear margins and normal, benign or class 2 cytology within 6-24 months.
‡Possible or definite high-grade cytological abnormality, excluding smears within six months after a procedure. §A positive smear not followed by a procedure which was probably curative within six months. Table 3 . Three of these women were diagnosed with ≥1B carcinoma within a year of the stage 1A diagnosis. While the diagnosis of stage 1A was reviewed and invasion of >5 mm was excluded in the available material, it is likely that for these women there was a focus of invasion which had not been excised. None †Classification of initial management based on procedures, examination of the excision margins and cytology 6-24 months after the procedure. Probably non-curative, small = persisting disease, small excision; Probably non-curative, large = persisting disease large excision; Probably curative = either: (i) hysterectomy with clear or unknown margins and normal, benign, class 2 or no informative cytology within 6-24 months; or (ii) cone biopsy with clear margins and normal, benign or class 2 cytology within 6-24 months.
‡Positive cytology = class 3, 4 or high grade; negative cytology = normal, benign or class 2; none = no informative smears within 6-24 months after the procedure. §Diagnosed with stage 1A carcinoma of the cervix during follow-up after diagnosis with cervical intraepithelial neoplasia (CIN3). ICD, International Classification of Diseases.
F I G U R E 2
Cumulative incidence of invasive cancer of the cervix (stage 1B or higher) or vaginal vault up to 30 years after diagnosis with stage 1A cancer of the cervix, according to initial management.
low-grade cytology after her hysterectomy, but she then had 11 untreated positive smears and four small biopsies, before being diagnosed with stage 1B carcinoma of the cervix 31 years after her diagnosis with stage 1A carcinoma. Thus, neither of these two women appeared to receive appropriate surveillance or treatment after initial treatment that was deemed to be probably curative.
For three women it was not possible to judge from stored specimens whether their initial diagnosis was stage 1A1 or 1A2.
None of these women developed invasive carcinoma, although Green's policy of following women with diagnosed but untreated (or under-treated) lesions was responsible for the excess of inappropriate follow-up interventions among women whose initial management was not curative, compared to those with initial curative treatment.
The outcomes for these women with microinvasive cancer have not been reported previously, either because they were (appropriately) excluded at the outset from analyses of CIN3, [3] [4] [5] or,
for those diagnosed after their initial CIN3 diagnosis, Stage 1A carcinoma served as an endpoint in the previous analyses. 4, 5 The latter group are included in our present study, because the majority were managed during the period of the clinical study. Of the eight deaths reported here, only two were in the latter group and these deaths had been counted in our previous analysis of outcomes for women with CIN3.
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The types of non-curative initial management for microinvasive cancer differ from the initial management for women with CIN3 previously reported. 5 For women with microinvasive cancer, the entire lesion had to be removed to make the diagnosis It also needs to be remembered that the women in Green's study
were not asked to consent to the management approach being followed, and most were unaware that they were not receiving conventional treatment.
We are reporting these findings in order to document and acknowledge the harm suffered by these women, and also to complete the picture of the effects of Green's study.
